Therapeutic targeting of endothelial calcium signaling accelerates the resolution of lung injury
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-18 23:44
摘要：
VT-109, a synthetic cyclic inhibitor of EB3, shows significant promise in treating acute respiratory distress syndrome (ARDS) by targeting endothelial calcium signaling. In preclinical models, VT-109 restores lung function, reduces vascular leakage, and activates the FOXM1 reparative program, highlighting its potential as a broad-spectrum therapeutic intervention for ARDS, particularly in the context of COVID-19. The compound exhibits a favorable safety profile and pharmacokinetics, warranting further clinical investigation.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分+重点关注领域符合度
business_impact
0.8分+获得投资
scientific_rigor
1.5分+具体实验数据支持
timeliness_innovation
1.5分+重大创新
investment_perspective
2.5分+早期研发
market_value_relevance
1.0分+高发疾病
team_institution_background
0.5分+知名机构
technical_barrier_competition
1.0分+技术壁垒高
关键证据
VT-109 effectively mitigates vascular leakage and restores lung function in multiple ARDS models.
The study demonstrates the activation of the FOXM1 reparative program in endothelial cells.
VT-109 shows a broad safety margin and favorable pharmacokinetics.
真实性检查
否
AI评分总结
VT-109, a synthetic cyclic inhibitor of EB3, shows significant promise in treating acute respiratory distress syndrome (ARDS) by targeting endothelial calcium signaling. In preclinical models, VT-109 restores lung function, reduces vascular leakage, and activates the FOXM1 reparative program, highlighting its potential as a broad-spectrum therapeutic intervention for ARDS, particularly in the context of COVID-19. The compound exhibits a favorable safety profile and pharmacokinetics, warranting further clinical investigation.